FGF21 targets pathways which enhance insulin sensitivity in brown adipose but not skeletal muscle in mice
Endocrinology · 2026-04-07 · 167 (5)
DOI: 10.1210/endocr/bqag040 ↗At a glance
Journal article in Endocrinology, published online on 2026-04-02. Written by Matthew C Juber and 4 co-authors. Institution: Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA. Major MEDLINE topics: Fibroblast Growth Factors, Muscle, Skeletal, Insulin Resistance, Adipose Tissue, Brown. 55 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: BLRD VA, NIA NIH HHS, NIDDK NIH HHS.
Abstract (original language)
Acute pharmacological administration of the endocrine hormone fibroblast growth factor 21 (FGF21) enhances insulin sensitivity. This acute insulin-sensitizing effect of FGF21 is mediated through direct signaling to brown adipose tissues. Since skeletal muscle is an important site of insulin-stimulated glucose intake and shares a common progenitor cell with brown adipocytes, we examined whether the beneficial effects of FGF21 administration could be enhanced by making skeletal muscle a FGF21-responsive target tissue. This was accomplished by ectopically expressing the FGF21 co-receptor, β-klotho, in skeletal muscle. Here, we demonstrate that under normal conditions, FGF21 does not enhance insulin-stimulated glucose uptake in skeletal muscle. In addition, generation of FGF21 responsiveness and direct signaling to skeletal muscle also has no effect on FGF21-mediated increases in whole-body or skeletal muscle insulin sensitivity. Instead, FGF21 uniquely signals to brown adipocytes to enhance insulin-stimulated glucose uptake. Therefore, to identify how FGF21 signals to brown adipocytes to enhance insulin sensitivity, we performed comprehensive phospho-proteomics in brown adipocytes in response to FGF21 and/or insulin. Our results indicate that FGF21 administration increases the phosphorylation of several proteins involved in the trafficking of GLUT4 in primary brown adipocytes. These results provide new insights into how FGF21 enhances insulin sensitivity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.
- Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA.
- Elizabeth Weiser Caswell Diabetes Institute, University of Michigan, Ann Arbor, MI 48109, USA.
- Life Science Institute, University of Michigan, Ann Arbor, MI 48109, USA.
- Harold Hamm Diabetes Center, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
- Department of Biochemistry and Physiology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
ORCID profiles: Matthew J Potthoff
Funding
- BLRD VA
- NIA NIH HHS
- NIDDK NIH HHS
Cite
APA
Juber, M. C., King-McAlpin, S., Buscaglia, P., Sebag, J. A., & Potthoff, M. J. (2026). FGF21 targets pathways which enhance insulin sensitivity in brown adipose but not skeletal muscle in mice. Endocrinology, 167(5). https://doi.org/10.1210/endocr/bqag040
Vancouver
Juber MC, King-McAlpin S, Buscaglia P, Sebag JA, Potthoff MJ. FGF21 targets pathways which enhance insulin sensitivity in brown adipose but not skeletal muscle in mice. Endocrinology. 2026;167(5). doi:10.1210/endocr/bqag040
BibTeX
@article{Juber2026,
author = {Juber, Matthew C and King-McAlpin, Sheps and Buscaglia, Paul and Sebag, Julien A and Potthoff, Matthew J},
title = {FGF21 targets pathways which enhance insulin sensitivity in brown adipose but not skeletal muscle in mice},
journal = {Endocrinology},
year = {2026},
volume = {167},
number = {5},
doi = {10.1210/endocr/bqag040}
}
EUVIMED